About Genocea

Genocea is developing therapeutics at the forefront of the T cell revolution. T cells are increasingly recognized as a critical element of the body’s protective immune response to a wide range of pathogens and diseases.

While traditional immunotherapy discovery methods have largely used predictive algorithms to find target antigens, we have been able to successfully leverage ATLAS™, our proprietary, high-throughput technology platform, to identify target antigens of T cells based on actual human immune responses, enabling the rapid development of therapeutic vaccines that stimulate human protective immunity. We have advanced our lead candidate, GEN-003, a novel T cell-enabled immunotherapy for genital herpes, into Phase 2 clinical development, while also exploring earlier-stage candidates in immuno-oncology.

adjusted-apc-t-cell-image2

Stock Quote

NASDAQ GNCA
$4.39
+ 0.01 (+0.23%)


0.21M

Volume

$4.50

Day High

$4.36

Day Low

Jan 13, 2017 ET on 4:00 PM Delayed at least 20 minutes.

Stock Chart



Webcasts

Jan 5, 2017 at 9:00 AM ET
Dec 14, 2016 at 8:30 AM ET